免疫检查点阻断（ICB）疗法彻底改变了癌症治疗，但对妇科癌症的疗效有限。 VISTA（T 细胞激活的 V 结构域 Ig 抑制因子）是 B7 家族的成员，正在成为调节肿瘤微环境内抗肿瘤免疫反应的另一个检查点。本文综述了VISTA的结构、表达和作用机制。此外，它还强调了 VISTA 阻断疗法的最新进展及其在改善妇科癌症患者预后方面的潜力。通过了解 VISTA 在介导妇科肿瘤免疫逃逸中的作用，我们可以开发更有效的组合治疗策略，从而克服对当前 ICB 疗法的耐药性。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment but has shown limited efficacy in gynecologic cancers. VISTA (V-domain Ig suppressor of T-cell activation), a member of the B7 family, is emerging as another checkpoint that regulates the anti-tumor immune responses within the tumor microenvironment. This paper reviews the structure, expression, and mechanism of action of VISTA. Furthermore, it highlights recent advances in VISTA-blocking therapies and their potential in improving outcomes for patients with gynecologic cancers. By understanding the role of VISTA in mediating the immune evasion of gynecologic tumors, we can develop more effective combinatory treatment strategies that could overcome resistance to current ICB therapies.Copyright © 2024 Elsevier B.V. All rights reserved.